Weekly Research Analysts’ Ratings Updates for Tenax Therapeutics (TENX)

Several brokerages have updated their recommendations and price targets on shares of Tenax Therapeutics (NASDAQ: TENX) in the last few weeks:

• 8/11/2026 – Tenax Therapeutics was given a new $4.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 8/11/2026 – Tenax Therapeutics was given a new $4.00 price target by Guggenheim. They now have a “buy” rating on the stock.
• 8/11/2026 – Tenax Therapeutics had its “buy” rating reaffirmed by Guggenheim.
• 8/11/2026 – Tenax Therapeutics was given a new $4.00 price target by Leerink Partners.
• 8/11/2026 – Tenax Therapeutics had its “neutral” rating reaffirmed by Chardan Capital. They now have a $5.00 price target on the stock.
• 8/11/2026 – Tenax Therapeutics was downgraded by Evercore Inc from “outperform” to “in-line”. They now have a $5.00 price target on the stock.
• 8/10/2026 – Tenax Therapeutics was downgraded by William Blair from “outperform” to “market perform”.
• 8/10/2026 – Tenax Therapeutics was given a new $5.00 price target by Roth Capital.
• 7/31/2026 – Tenax Therapeutics had its “buy” rating reaffirmed by Chardan Capital. They now have a $27.00 price target on the stock.
• 7/29/2026 – Tenax Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $35.00 price target on the stock.
• 7/28/2026 – Tenax Therapeutics is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $35.00 price target on the stock.
• 7/22/2026 – Tenax Therapeutics is now covered by Evercore Inc. They set an “outperform” rating and a $39.00 price target on the stock.
• 7/2/2026 – Tenax Therapeutics had its “buy” rating reaffirmed by Chardan Capital. They now have a $27.00 price target on the stock.
• 6/30/2026 – Tenax Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/24/2026 – Tenax Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $35.00 price target on the stock.
• 6/22/2026 – Tenax Therapeutics had its “buy” rating reaffirmed by Guggenheim. They now have a $40.00 price target on the stock, up from $34.00.
• 6/22/2026 – Tenax Therapeutics is now covered by Chardan Capital. They set a “buy” rating and a $27.00 price target on the stock.
• 6/12/2026 – Tenax Therapeutics had its price target raised by Piper Sandler from $20.00 to $50.00. They now have an “overweight” rating on the stock.

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.